Business Wire

NEUSTAR

16.9.2020 09:32:11 CEST | Business Wire | Press release

Share
DDoS Attacks Increase by 151% in First Half Of 2020

Neustar, Inc. , a global information services and technology company and leader in identity resolution, today released its latest cyberthreats and trends report which identifies significant shifts in distributed denial-of-service (DDoS) attack patterns in the first half of 2020. Neustar’s Security Operations Centre (SOC) saw a 151% increase in the number of DDoS attacks compared to the same period in 2019. These included the largest and longest attacks that Neustar has ever mitigated at 1.17 Terabits-per-second (Tbps) and 5 days and 18 hours respectively. These figures are representative of the growing number, volume and intensity of network-type cyberattacks as organisations shifted to remote operations and workers’ reliance on the internet increased.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005046/en/

Neustar’s role in providing navigation for internet requests (via its global UltraDNS network) and in detecting and mitigating threats (through its UltraDDoS Protect service) has given the company a front-row seat from which to observe macro cyberattack trends, as detailed in its CyberThreats and Trends Report: Jan-Jun 2020.

Largest and smallest DDoS attacks becoming increasingly intense and sophisticated

Large DDoS attacks are bigger, more intense, and happening in greater numbers than ever before. There has been a noticeable spike in large attacks across the industry, most notably the 2.3 Tbps attack targeting an Amazon Web Services client in February – the largest volumetric DDoS attack on record.

Neustar saw the total number of attacks increase by over two and a half times during January through June of 2020 compared to the same period in 2019. The increase was felt across all size categories, with the biggest growth happening at opposite ends of the scale – the number of attacks sized 100 Gbps and above grew a whopping 275% and the number of very small attacks, sized 5 Gbps and below, increased by more than 200%. Overall, small attacks sized 5 Gbps and below represented 70% of all attacks mitigated by Neustar between January and June of 2020.

“While large volumetric attacks capture attention and headlines, bad actors increasingly recognise the value of striking at low enough volume to bypass the traffic thresholds that would trigger mitigation to degrade performance or precision target vulnerable infrastructure like a VPN,” said Michael Kaczmarek, Neustar Vice President of Security Products. “These shifts put every organisation with an internet presence at risk of a DDoS attack – a threat that is particularly critical with global workforces reliant on VPNs for remote login. VPN servers are often left vulnerable, making it simple for cybercriminals to take an entire workforce offline with a targeted DDoS attack."

The rise in smaller DDoS attacks has been matched by increases in attack sophistication and intensity. 52% of threats mitigated by Neustar leveraged three vectors or more, with the number of attacks featuring a single vector essentially nonexistent. Neustar also tracked new amplification methods and attacks of higher intensity targeted at critical pieces of web infrastructure. The previous high-water mark of 500 millions-of-packets-per-second (Mpps) was topped this year, with an attack of over 800 Mpps recorded.

“The dependency and growth in online communications since COVID-19 has fundamentally changed what organisations must do to succeed,” said Brian McCann, President, Neustar Security Solutions. “There is no one-size-fits-all solution for security, but having a reliable cloud service that ensures availability and security for all services and users has proven to be a critical difference between barely surviving and thriving in this rapidly changing environment.”

Ongoing impact of COVID-19 on cyberthreats and industry web traffic

The precipitous rise in DDoS attacks mirrors the growth in internet traffic seen during the pandemic. Internet use is up between 50% and 70% and streaming media rose more than 12% in the first quarter of 2020 . This has meant that attackers of all types, whether serious cybercriminals or bored teenagers stuck at home, have had more screen time to be disruptive.

In a study of one of the largest cybercrime sites by Cambridge University’s Cybercrime Centre , they found that the number of attacks enacted by the website went up sharply at the start of the pandemic and associated lockdown. They also found that instead of existing cybercriminals staging more attacks, it was new attackers driving the increase in DDoS attacks.

The corresponding attacks, like internet traffic, have not been evenly spread across all websites. It’s well known that ecommerce and gaming websites have received a lot of negative attention from hackers, but there are other industries that have been hit hard by cybercriminals over the last six months. Healthcare organisations contain sensitive patient information and a growing number of IoT devices that are easily exploited. Combined with the additional pressure of the pandemic, hospitals have become some of the most desirable targets for cybercriminals. Industries that have seen a lot of growth during the pandemic, like online gambling, have also been ripe for cyberthreats. Most notably, online video has seen an incredible rise in both usage and DDoS attacks. Omdia has reported an additional 200 billion hours of Netflix viewing or Zoom video calls over initial 2020 forecasts. Where traffic rises, so too do attacks; Neustar attack mitigations for this vertical increased by 461% over the last six months.

“While 2020 has brought radical changes in behaviour to consumers and criminals alike, it is naïve to assume that actions of either audience will revert completely to pre-pandemic norms after this crisis passes,” added Kaczmarek. “Mitigating these increasingly sophisticated DDoS attacks will continue to be a necessary part of doing business online. At a time when many organisations could do with less worry, fully managed services can take the pressure off and ensure critical digital assets are safe and secure.”

The report highlights several emerging attacker tactics seen across the industry, including an increase in burst and pulse DDoS attacks, broadening abuse of built-in network protocols such as ARMS, WS-DD, CoAP and Jenkins to launch DDoS amplification attacks that can be carried out with limited resources and cause significant disruptions, NXNS attacks targeting DNS servers, RangeAmp attacks targeting Content Delivery Networks (CDNs), and a resurgence of Marai-like malware capable of building large botnets through the exploitation of poorly secured IoT devices.

A complimentary copy of Neustar’s CyberThreats and Trends Report 1H 2020 is available here .

-ENDS-

About Neustar

Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye